Vivanza Biosci. (530057)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 2916.67% shows significant top-line expansion, albeit from a low base.
• Latest quarterly sales of ₹45 Cr are large relative to the ₹20 Cr market cap, leaving room for operating leverage if margins materialize.
• Piotroski F-Score of 6/9 suggests moderate balance-sheet health, not an acutely failing enterprise.
• Trading at just ₹1.75 low earlier and now ₹4.93 indicates the market is paying attention to the sales inflection.

Concerns

• No real earnings: P/E is 0.00 and latest quarter net profit is ₹0 Cr, so there is no profit-based valuation anchor.
• Negative ROE of -6.55% and ROCE of -2.77% show the business is destroying shareholder capital at current operating levels.
• P/B of 3.85 is expensive when book value per share is ₹1.28 and returns are negative, leaving no margin of safety.
• Insufficient data: promoter holding is N/A and the FairStock Score is N/A, reducing transparency for a tiny ₹20 Cr microcap.

AI Analysis

Let me apply Graham's discipline: price is what you pay, value is what you get. At ₹4.93, Vivanza Biosci is trading at the very top of its 52-week range, and at 3.85 times book value. But book value is only ₹1.28 per share, and this business is not earning a return on that book. Return on equity is -6.55% and ROCE is -2.77%. Those are not numbers of a franchise with a moat; they are numbers of a business that burns capital. A P/E of 0.00 simply tells me there are no current earnings to justify. The latest quarter shows ₹45 crore of sales but ₹0 crore of net profit. Revenue growth of 2916.67% grabs headlines, but any business can inflate top line without creating shareholder value. Profit growth of 400% sounds exciting, but with net profit at zero, it is not economically meaningful. The market cap is just ₹20 crore, making this a microcap. Promoter holding is N/A, so I cannot even confirm alignment between management and minority shareholders. The Piotroski F-Score of 6/9 is moderate, but it is no substitute for consistent, profitable returns. Benjamin Graham would demand a margin of safety. Here, paying almost four times book for negative returns offers none. This may be an early-stage pharma turnaround, but the burden of proof is on management to convert sales into lasting profits and positive return on capital. Until then, this is speculation, not investment. I would keep it on the watch list, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer